# Care Capital

> Care Capital is a VC fund in Princeton backing Biotechnology and Health Care. See 25 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Princeton, United States
- Total investments: 25
- Last investment: Sep 2013
- Lead investor: 16%
- Last updated: Aug 2026
- Website: http://www.carecapital.com

Care Capital is a life sciences–focused venture capital firm that invests in entrepreneurial companies which are engaged in the development of pharmaceutical assets.The company provides its services to both private and public opportunities in the United States and Europe. It manages approximately $500 million in capital.Care Capital wasestablished in 2000 and is based in Princeton, New Jersey.

## Contacts

5 contacts available for Care Capital. Shizune tracks 8 team members at Care Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/care-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 48% |
| Health Care | 8 | 32% |
| Pharmaceutical | 8 | 32% |
| Medical Device | 5 | 20% |
| Biopharma | 2 | 8% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 24% |
| Series A | 4 | 16% |
| Series C | 3 | 12% |
| Funding Round | 3 | 12% |
| Series D | 2 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 48% |
| United Kingdom | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Lorenzo Pellegrini | Partner | 4 | https://shizune.co/investors/profile/lorenzo-pellegrini |
| Argeris Karabelas | Partner | 0 | https://shizune.co/investors/profile/argeris-karabelas |
| Daniel Cabo | CFO | 0 | https://shizune.co/investors/profile/daniel-cabo |
| David R. Ramsay | Partner and co-founder | 0 | https://shizune.co/investors/profile/david-r-ramsay |
| Jan Leschly | Founder, Chairman & Managing Partner | 4 | https://shizune.co/investors/profile/jan-leschly |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Inotek Pharmaceuticals | Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration(AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020. | $7M | Debt Financing | Sep 27, 2013 |  |
| Inotek Pharmaceuticals | Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration(AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020. | $21M |  | Sep 27, 2013 |  |
| Agile Therapeutics | Agile Therapeutics, Inc., a specialty pharmaceutical company, engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and Ethinylestradiol. The company was founded in 1997 as Levotech, Inc. and changed its name toAgile Therapeutics, Inc. in April 2001. It is based in Princeton, New Jersey. | $40M | Series C | Jul 19, 2012 |  |
| Elevation Pharmaceuticals | Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategicdecision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients. | $30M | Series B | Jan 04, 2012 |  |
| Elevation Pharmaceuticals | Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategicdecision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients. | $17M | Series A | Sep 26, 2011 |  |
| BioCritica | BioCritica is a biotechnology company focused on meeting the critical care needs of patients and clinicians in the hospital market. In addition to Xigris for the treatment of severe sepsis, BioCritica is developing a pipeline of other products. Their mission is to develop and commercialize products that make a dramatic improvement inpeople's lives. | $25M | Private Equity | May 25, 2011 |  |
| Agile Therapeutics | Agile Therapeutics, Inc., a specialty pharmaceutical company, engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and Ethinylestradiol. The company was founded in 1997 as Levotech, Inc. and changed its name toAgile Therapeutics, Inc. in April 2001. It is based in Princeton, New Jersey. | $45M | Series B | Jun 14, 2010 |  |
| Elevation Pharmaceuticals | Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategicdecision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients. | $30M | Series A | Jan 21, 2010 |  |
| MicroCHIPS | Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. Our proprietary microchip-based implant can store and release precise doses of drugs over months and years. The implant, which is placed under the skin by a trained physician during a simple office procedure using local anesthesia, can bewirelessly activated or deactivated by a physician or patient, without requiring removal. In addition, physicians can wirelessly modify the frequency or dose of the drug to meet the individual needs of each patient. | $16.5M |  | Jan 07, 2010 |  |
| Anacor Pharmaceutical | Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company’s primary product candidate, AN2690, is a novel topical antifungal forthe treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis. | $50M | Series E | Jan 06, 2009 |  |

10 of 25 investments shown.

## Co-investors
- [Rho Ventures](https://shizune.co/investors/profile/rho-ventures) — VC Fund, 9 deals together
- [MedImmune Ventures](https://shizune.co/investors/profile/medimmune-ventures) — VC Fund, 6 deals together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 5 deals together
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund, 4 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 3 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Care Capital invest in?

Care Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Care Capital?

Public channels for Care Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Care Capital?

The team at Care Capital includes Lorenzo Pellegrini (Partner), Argeris Karabelas (Partner) and Daniel Cabo (CFO), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co